Search Results
Your search for 3 matches 15327 pages
Showing 10401 - 10450Weekly Vinblastine in Chemotherapy-Naive Children With Progressive Low-Grade Glioma
In a phase II Canadian Pediatric Brain Tumor Consortium Study reported in the Journal of Clinical Oncology, Lassaletta et al found that vinblastine monotherapy was associated with response or stable disease in most children with chemotherapy-naive low-grade glioma. Vinblastine monotherapy has shown ...
Study Suggests No Evidence for Screening Mammography Cutoff Age
An analysis of data from nearly 6 million screening mammograms found no evidence for a clear cutoff age to stop breast cancer screening. Screening mammography among women aged 75 years was associated with higher cancer detection and lower recall rates than among younger women in the study. These...
Exploring Practical Strategies for Cancer Care in Low-Resource Settings
One of the featured “Big Debates” at the 2016 World Cancer Congress in Paris addressed this question: Are scarce resources best applied to prevention rather than treatment? Many experts do not see prevention vs treatment in such stark terms or even as a realistic scenario. It’s a false dichotomy,...
Co-occurrence of Cancer and Cognitive Impairment in Older Adults
The prevalence of both cancer and cognitive impairment increases with age.1-3 Based upon Surveillance, Epidemiology, and End Results (SEER)-Medicare studies, it is estimated that 3% to 7% of patients with cancer aged ≥ 65 also suffer from dementia, although the true prevalence of dementia in this...
The Best of SIO
The following five abstracts were chosen as the best submitted studies presented at this year’s International Conference of the Society for Integrative Oncology (SIO). They represent a diverse group of integrative therapies and interventions in the care of patients with cancer, including an...
Expert Point of View: Carlos L. Arteaga, MD
Press conference moderator Carlos L. Arteaga, MD, of Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, said that buparlisib will probably not be clinically useful, partly because it crosses the blood-brain barrier , thus causing mood disorders, and is not an ideal phosphoinositide 3-kinase...
Buparlisib Phase III Findings: Glass Half Empty or Half Full?
The pan-phosphoinositide 3-kinase (PI3K) inhibitor buparlisib combined with fulvestrant (Faslodex) prolonged progression-free survival compared with placebo and fulvestrant in postmenopausal women with hormone receptor–positive, HER2-negative advanced breast cancer previously treated with an...
Pathologic Complete Response Not Boosted by Addition of Estrogen Deprivation to Chemotherapy and Dual HER2 Blockade
The addition of estrogen deprivation to neoadjuvant chemotherapy and HER2 blockade did not enhance the achievement of pathologic complete responses in women with early-stage breast cancer, according to the results of the NRG Oncology/NSABP B-52 trial reported at the 2016 San Antonio Breast Cancer...
Expert Point of View: Carlos L. Arteaga, MD
Press conference moderator Carlos L. Arteaga, MD, said: “This drug is not necessarily the same as palbociclib [Ibrance] or ribociclib. There are subtle differences among these three [cyclin-dependent kinase (CDK) 4/6] inhibitors. The tissue analysis provides us with an enormous opportunity to...
Abemaciclib Plus Anastrozole: Promising Signals Reported in Phase II Study of Early Breast Cancer
As neoadjuvant therapy, abemaciclib alone or in combination with anastrozole achieved strong signals of anticancer activity in postmenopausal patients with hormone receptor–positive, HER2-negative breast cancer in the neoMONARCH phase II study.1 Abemaciclib alone or in combination with anastrozole...
Genomic Landscape of Metastatic Breast Cancer Differs From That of Primary Breast Cancer
Researchers working on whole-exome and transciptome sequencing of endocrine-resistant estrogen receptor–positive metastatic breast cancer have shown that the mutational landscape differs from that of estrogen receptor–positive primary breast cancer, and these differences have the potential to...
Fulvestrant Plus Everolimus: New Second-Line Option for Postmenopausal Metastatic Breast Cancer
The addition of everolimus (Afinitor) to fulvestrant (Faslodex) doubled progression-free survival in postmenopausal women with hormone receptor–positive, HER2-negative metastatic breast cancer resistant to aromatase inhibitor therapy compared with fulvestrant plus placebo, according to the...
Oncology Organizations Applaud Passage of the 21st Century Cures Act
On Tuesday, December 13, President Obama signed into law the 21st Century Cures Act, landmark legislation designed to improve and accelerate the pace of biomedical research in the United States. ASCO Chief Executive Officer Clifford Hudis, MD, FACP, FASCO, attended the White House signing ceremony ...
FDA Permits Marketing of New Tissue Expander for Women Undergoing Breast Reconstruction Following Mastectomy
On December 21, the U.S. Food and Drug Administration (FDA) allowed marketing of a new tissue-expander system for soft-tissue expansion in two-stage breast reconstruction following mastectomy and in the treatment of underdeveloped breasts and soft-tissue deformities. A patient uses a dose...
Expert Point of View: Armand Keating, MD
“This study shows that a great deal of innovation can come from existing knowledge. The 7+3 regimen has been around since I was an intern,” admitted Armand Keating, MD, of the University of Toronto and Princess Margaret Hospital, Toronto, Ontario, Canada. “Using the liposomal formulation of...
CPX-351 Improves Survival Post Transplant in Older High-Risk Patients With Acute Myeloid Leukemia
Induction therapy with the experimental chemotherapy called CPX-351—a liposomal formulation of cytarabine and daunorubicin—outperformed standard “7+3” cytarabine plus daunorubicin by extending survival in older high-risk patients with acute myeloid leukemia (AML) who subsequently underwent...
Vadastuximab Talirine Shows Early Promise in Newly Diagnosed Acute Myeloid Leukemia
The investigational CD33-directed antibody-drug conjugate vadastuximab talirine yielded high overall and complete response rates when combined with standard “7+3” chemotherapy for patients newly diagnosed with acute myeloid leukemia.1 Results from this phase Ib study were presented at the 2016...
2017 Oncology Meetings
JANUARY 2017 2017 Oncologic Emergency Medicine ConferenceJanuary 12-13 • Houston, Texas For more information: www.mdanderson.org/education-training/professional-education/cme-conference-management/conferences/oncologic-emergency-medicine-conference.html 2017 Highlights of ASH in North...
Weighing the Benefits and Risks of Medical Marijuana
Despite the fact that 28 states and the District of Columbia have enacted laws to permit the use of cannabis and cannabinoid-based drugs to treat medical conditions, including cancer and symptoms from its treatment, federal law prohibits physicians from prescribing marijuana to their patients,...
Dose-Adjusted EPOCH-R No Better Than R-CHOP in Diffuse Large B-Cell Lymphoma
Long-awaited results of the Cancer and Leukemia Group B (CALGB)/Alliance 50303 trial were a disappointment to many hematologists/oncologists at the 2016 American Society of Hematology (ASH) Annual Meeting & Exposition. The study failed to show that dose-adjusted EPOCH-R (etoposide,...
Accelerating Progress in the Treatment of Glioblastoma Multiforme
W.K. Alfred Yung, MD, has wanted a career in medicine since he was a high-school student and has spent nearly 4 decades fulfilling that dream, specifically in the research and treatment of one of the deadliest cancers, malignant brain tumor, especially glioblastoma multiforme, the most common...
Obinutuzumab Prolongs Disease-Free Survival vs Rituximab in Follicular Lymphoma
Induction and maintenance therapies with obinutuzumab (Gazyva) were superior to rituximab (Rituxan) induction and maintenance in patients with untreated follicular lymphoma, according to results of the phase III GALLIUM study presented at the Plenary Session during the 58th American Society of...
Updated ASTRO Guideline Expands Pool of Suitable Candidates for Accelerated Partial-Breast Irradiation
On November 17, 2016, the American Society for Radiation Oncology (ASTRO) issued an updated clinical practice statement for accelerated partial-breast irradiation for early-stage breast cancer. The updated guideline reflects recent evidence that greater numbers of patients may benefit from...
Mutational Characteristics of Chemotherapy-Treated Bladder Urothelial Neoplasms
Radical cystectomy with urinary diversion is the standard of care for muscle invasive bladder cancer.1 Meta-analyses of prospective data have shown a 5% overall survival benefit at 5 years for those receiving neoadjuvant systemic chemotherapy prior to cystectomy.2,3 We currently know of two...
Confirmation or Transformation? The Case of Palbociclib in Hormone Receptor–Positive Metastatic Breast Cancer
Women with hormone receptor–positive metastatic breast cancer are witnessing an unprecedented time of success in the battle against their disease. Just in the past 12 months, a number of prospective, randomized, phase III studies were reported, with positive results indicating the value of...
Addition of Palbociclib to Letrozole in Previously Untreated Advanced Estrogen Receptor–Positive, HER2-Negative Breast Cancer
In the phase III PALOMA-2 trial reported in The New England Journal of Medicine, Richard S. Finn, MD, of the David Geffen School of Medicine at the University of California, Los Angeles, and colleagues found that the addition of palbociclib (Ibrance) to letrozole significantly improved...
Expert Point of View: Sergio A. Giralt, MD
Sergio A. Giralt, MD, Chief of the Adult Bone Marrow Transplant Service at Memorial Sloan Kettering Cancer Center, New York, and the Melvin Berlin Family Chair in Multiple Myeloma, commented on the findings of the StaMINA trial for The ASCO Post. He said the results of the largest randomized U.S....
Women in Oncology: Breaking Down Barriers and Looking to the Future
There has been no better time than the present for women in the field of oncology: Women at all stages of their careers are finding more opportunities and avenues to excel. At the time of the last ASCO workforce survey, women made up 28.4% of the oncologist workforce, and that proportion is rising...
Achieving Complete Response Is Key to Improving Survival in Older Patients With AML
The importance of achieving complete response after intensive therapy in older adults with acute myeloid leukemia (AML) was confirmed in a follow-up analysis of the E2906 North American Intergroup trial.1 Patients in complete response had superior survival in this landmark analysis. This finding...
Reducing Doses and Stopping Tyrosine Kinase Inhibitors Gain Favor in Chronic Myeloid Leukemia
Tyrosine kinase inhibitors, such as imatinib, nilotinib (Tasigna), and dasatinib (Sprycel), have revolutionized the treatment of chronic myeloid leukemia (CML). A substantial percentage of patients achieve deep and meaningful remissions on these agents. More recently, partly driven by patients’ and ...
Reduced-Intensity Chemotherapy Leads to More Relapses in Childhood ALL
Children with acute lymphoblastic leukemia (ALL) considered at standard risk for relapse should continue to receive standard-intensity regimens, according to findings from the international randomized AIEOP-BFM ALL 2000 trial.1 A reduced-intensity treatment for children with ALL considered to have ...
A Gleason 6 Tumor: Is It Cancer, and Should It Be Treated?
The diagnosis and treatment of prostate cancer have long been a source of controversy among the oncology community, the political sector, and patient advocacy groups. Most notably, the decision to biopsy a man’s prostate gland rests largely on his prostate-specific antigen (PSA) test numbers, the...
As We Strive for a Cancer Cure, We Must Not Forget the Survivors
Although a cure for cancer remains elusive, there are many promising ideas to eradicate this disease, including the Cancer Moonshot Initiative and an ever-increasing body of cancer research that continually drives innovative treatments in an effort to improve survival and, ultimately, find a...
Benefit of Extended Adjuvant Endocrine Therapy Not Upheld in Multiple Studies Reported in San Antonio
Extended endocrine therapy with an aromatase inhibitor did not improve disease-free survival in patients with hormone receptor–positive breast cancer enrolled in three studies presented at the 2016 San Antonio Breast Cancer Symposium. The results stand in contrast to the phase III National Cancer...
Atezolizumab Shows Activity in First-Line Treatment of Cisplatin-Ineligible Patients With Advanced Urothelial Carcinoma
In a phase II trial reported in The Lancet, Balar et al found that first-line atezolizumab (Tecentriq) produced durable responses in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma. In the study, 119 patients from 47 sites in North America and Europe who were ...
ESMO Asia 2016: Study Validates Set of Six Adaptable Prognosis Prediction Models for Patients With Cancer in Palliative Care Settings
A routine blood test may predict how long patients with cancer in palliative care will survive, researchers reported at the ESMO Asia 2016 Congress in Singapore. “Cancer patients in palliative care want honest and accurate prognostic information but this information needs to be shared...
Atezolizumab Improves Survival vs Docetaxel in Previously Treated Non–Small Cell Lung Cancer
In the phase III OAK trial reported in The Lancet by Rittmeyer et al, treatment with the anti–programmed cell death ligand 1 (PD-L1) antibody atezolizumab (Tecentriq) improved overall survival vs docetaxel in previously treated non–small cell lung cancer (NSCLC). Results of the trial...
ESMO Asia 2016: Asian Patients With Head and Neck Squamous Cell Carcinoma Live Longer With Immunotherapy Than Overall Population
Asian patients with head and neck cancer live longer with pembrolizumab (Keytruda) immunotherapy than the overall population, according to a subanalysis of the KEYNOTE-012 trial presented at the ESMO Asia 2016 Congress in Singapore. “Head and neck squamous cell carcinoma is the seventh most...
Study Finds Regorafenib Improves Survival in Patients With Hepatocelluar Carcinoma Progressing on Sorafenib
Regorafenib (Stivarga) improved overall survival vs placebo in patients with hepatocellular carcinoma who had experienced disease progression on sorafenib (Nexavar) treatment, according to the phase III RESORCE trial reported by Bruix et al in The Lancet. Study Details In this double-blind trial, ...
Effect of Inpatient Palliative Care on Quality of Life After Stem Cell Transplant
Integrating palliative care into the treatment of patients undergoing hematopoietic stem cell transplantation for cancers like leukemia and lymphoma can improve their quality of life, relieve symptoms associated with the procedure, and reduce depression and anxiety, not only during the 3- to 4-week ...
WCLC 2016: Icotinib May Improve Progression-Free Survival vs Whole-Brain Irradiation in Patients With NSCLC With Brain Metastases
Patients whose lung cancer spreads to their brain typically have only 4 to 6 months left to live, but research presented by Chinese doctors suggests that using icotinib increases progression-free survival in these patients compared to whole-brain irradiation and chemotherapy combined. Yi-Long Wu,...
First-in-Class Rovalpituzumab Tesirine Active in Recurrent Small Cell Lung Cancer
In a phase I study reported in The Lancet Oncology, Rudin et al found that rovalpituzumab tesirine, a first-in-class antibody-drug conjugate directed against delta-like protein 3 (DLL3), produced responses in patients with recurrent small cell lung cancer (SCLC). DLL3 is a target identified in...
ASCO Clinical Practice Guideline on Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers
As reported in the Journal of Clinical Oncology by Saro H. Armenian, DO, MPH, of City of Hope, and colleagues, ASCO has released a clinical practice guideline on prevention and monitoring of cardiac dysfunction in survivors of adult cancers. Recommendations were developed by an expert panel using a ...
ESMO Asia 2016: Patients in India Wait an Average of 4 Months Before Seeking a Cancer Diagnosis
Patients in Chandigarh, India, waited an average of 4 months before seeking a cancer diagnosis, according to a recent study. Some patients waited less than a week before seeing a doctor—while others waited 3 years. The researchers will report their findings at the ESMO Asia 2016 Congress ...
WCLC 2016: Phase II LUME-Meso Trial on Oral Nintedanib in Mesothelioma Demonstrates Meaningful Clinical Benefit
The LUME-Meso phase II trial in patients with unresectable malignant pleural mesothelioma met its primary endpoint of progression-free survival. The data, presented at the 17th IASLC World Conference on Lung Cancer (WCLC) in Vienna (Abstract 4191 #OA22.02), showed nintedanib (Ofev) plus...
Promising Activity Seen With First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small Cell Lung Cancer
As reported in The Lancet Oncology by Hellman et al, the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) showed promising activity as first-line treatment in patients in the non–small cell lung cancer (NSCLC) cohort of the phase I CheckMate 012 study. Study Details In the...
Osimertinib Improves Progression-Free Survival vs Platinum/Pemetrexed in EGFR T790M–Positive NSCLC
In the phase III AURA3 trial reported in The New England Journal of Medicineby Mok et al, osimertinib (Tagrisso) significantly improved progression-free survival (PFS) vs platinum/pemetrexed (Alimta) among patients with epidermal growth factor receptor (EGFR) T790M–positive non–small...
ASCO CEO Dr. Clifford Hudis Commends President Obama, Vice President Biden, and Congress During 21st Century Cures Act Signing Ceremony
On Tuesday, December 13, President Obama signed into law the 21st Century Cures Act, landmark legislation designed to improve and accelerate the pace of biomedical research in the United States. ASCO Chief Executive Officer Clifford Hudis, MD, FACP, FASCO, attended the White House signing ceremony...
Rucaparib Appears Effective in Relapsed Platinum-Sensitive High-Grade Ovarian Carcinoma
In part 1 of the phase II ARIEL2 trial reported in The Lancet Oncology, Swisher et al found that the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib was associated with prolonged progression-free survival among patients with relapsed platinum-sensitive high-grade ovarian carcinoma who had...
Phase III Trial Shows Improved Progression-Free Survival With Fulvestrant vs Anastrozole in Hormone Receptor–Positive Advanced Breast Cancer
In the international phase III FALCON trial reported in The Lancet, Robertson et al found that progression-free survival was improved with intramuscular fulvestrant (Faslodex) vs oral anastrozole in endocrine therapy–naive women with hormone receptor–positive locally advanced or...
